ClinicalTrials.gg
CompletedNCT01852682Updated Nov 13, 2014

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

A Phase 3 interventional study of PA21 in Peritoneal Dialysis and Hyperphosphatemia, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-11-13.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.

Phase 3
23 of 41
3 open now
Registered
21st of 41
by date
Lead sponsor
5 of 41
Kissei Pharmaceutical Co., Ltd.

Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is one of 23 in phase 3, and was the 21st registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 20 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Hyperphosphatemia with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

03

Conditions studied

  • Peritoneal Dialysis
  • Hyperphosphatemia

Browse trials for

Keywords

  • Peritoneal Dialysis
  • Hyperphosphatemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving stable maintenance peritoneal dialysis
  • Peritoneal dialysis patients with hyperphosphatemia

Exclusion criteria

Exclusion Criteria:

  • Patients having history of a pronounced brain / cardiovascular disorder
  • Patients having severe gastrointestinal disorders
  • Patients having severe hepatic disorders
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)

Study arms

  • Experimental
    PA21

    Drug: PA21

Interventions

06

What researchers measure

Primary outcomes

  1. Serum phosphate concentrations

    Time frame: 12 weeks

Secondary outcomes

  1. Incidences of Adverse Events

    Time frame: 12 weeks

  2. Incidences of Adverse Events

    Time frame: 28 weeks

  3. Serum phosphate concentrations

    Time frame: 28 weeks

07

Study locations

1 site
  • Tokyo and Other Japanese City, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01852682
Responsible party
Sponsor
First posted
May 14, 2013
Primary completion
Mar 2014
Last update
Nov 13, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA21

Start the discussion